American Association for Cancer Research
10780432ccr204443-sup-255437_2_supp_6847018_qmxyfb.pdf (136.7 kB)

Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Download (136.7 kB)
journal contribution
posted on 2023-03-31, 22:31 authored by Tom van den Ende, Nicolien C. de Clercq, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, E.D. Geijsen, R.H.A. Verhoeven, Sybren L. Meijer, Sandor Schokker, M.P.G. Dings, Jacques J.G.H.M. Bergman, Nadia Haj Mohammad, Jelle P. Ruurda, Richard van Hillegersberg, Stella Mook, Max Nieuwdorp, Tanja D. de Gruijl, Tanya T.D. Soeratram, Bauke Ylstra, Nicole C.T. van Grieken, Maarten F. Bijlsma, Maarten C.C.M. Hulshof, H.W.M. van Laarhoven

Figure S4. Cytotoxic lymphocytes between baseline and on-treatment.



The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-1 (PD-L1) inhibition for rEAC. Patients with rEAC received nCRT according to the CROSS regimen combined with five cycles of atezolizumab (1,200 mg). The primary endpoint was the feasibility of administering five cycles of atezolizumab in ≥75% patients. A propensity score–matched nCRT cohort was used to compare pathologic response, overall survival, and progression-free survival. Exploratory biomarker analysis was performed on repeated tumor biopsies. We enrolled 40 patients of whom 85% received all cycles of atezolizumab. Immune-related adverse events of any grade were observed in 6 patients. In total, 83% proceeded to surgery. Reasons for not undergoing surgery were progression (n = 4), patient choice (n = 2), and death (n = 1). The pathologic complete response rate was 25% (10/40). No statistically significant difference in response or survival was found between the PERFECT and the nCRT cohort. Baseline expression of an established IFNγ signature was higher in responders compared with nonresponders (P = 0.043). On-treatment nonresponders showed either a high number of cytotoxic lymphocytes (CTL) with a transcriptional signature consistent with expression of immune checkpoints, or a low number of CTLs. Combining nCRT with atezolizumab is feasible in patients with rEAC. On the basis of our exploratory biomarker study, future studies are necessary to elucidate the potential of neoadjuvant immunotherapy in patient subgroups.See related commentary by Catenacci, p. 3269

Usage metrics

    Clinical Cancer Research



    Ref. manager